Target General Information
Target ID T59328
Target Name Epidermal growth factor receptor
Synonyms EGFR-TK; Epidermal growth factor receptor ErbB-1; Epidermal growth factor receptor-tyrosine kinase; Receptor protein-tyrosine kinase ErbB-1; Proto-oncogene c-ErbB-1; EGFR
Target Type Successful
Gene Name EGFR
Biochemical Class Kinase
UniProt ID EGFR_HUMAN
Target Gene Expression Profiles in the Disease-Relevant Drug Targeted Tissue of the Patients and Healthy Individuals
Disease Breast cancer
Example drug Lapatinib Approved [538585], [1572592]
Tissue Breast tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.89
Z-score: -1.53
P-value: 1.04E-65
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: -0.95
Z-score: -1.79
P-value: 2.77E-16
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Lung cancer
Example drug Erlotinib Approved [468098], [527466], [1572592]
Tissue Lung tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.04
Z-score: -0.09
P-value: 1.65E-01
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: -0.21
Z-score: -0.35
P-value: 1.58E-03
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Rectal cancer
Example drug Cetuximab Approved [527466], [541939], [1572592]
Tissue Rectal colon tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.25
Z-score: -1.63
P-value: 1.07E-02
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: -0.59
Z-score: -3.17
P-value: 1.24E-04
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Brain cancer
Example drug Rindopepimut Phase 3 [523703], [1572592]
Tissue Nervous tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.06
Z-score: 0.13
P-value: 8.30E-26
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Gastric cancer
Example drug DE-766 Phase 3 [550580], [550582], [1572592]
Tissue Gastric tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.42
Z-score: -2.17
P-value: 2.52E-01
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: 0.31
Z-score: 0.57
P-value: 2.59E-02
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Head and neck cancer
Example drug Zalutumumab Phase 3 [521892], [1572592]
Tissue Head and neck tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.32
Z-score: 0.55
P-value: 5.84E-05
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Melanoma
Example drug AZD9291 Phase 3 [525278], [542692], [1572592]
Tissue Skin
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.34
Z-score: -0.23
P-value: 1.60E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Bladder cancer
Example drug Gefitinib Phase 2 [468104], [536223], [1572592]
Tissue Bladder tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.09
Z-score: 0.29
P-value: 5.87E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Glioma
Example drug Erlotinib Phase 2 [468098], [527466], [1572592]
Tissue Brainstem tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.40
Z-score: 190.08
P-value: 2.09E-05
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Glioma
Example drug Erlotinib Phase 2 [468098], [527466], [1572592]
Tissue White matter
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.39
Z-score: 1.69
P-value: 6.32E-04
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Ovarian cancer
Example drug Gefitinib Phase 2 [468104], [536223], [1572592]
Tissue Ovarian tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.01
Z-score: -0.03
P-value: 9.25E-01
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: -1.28
Z-score: -2.32
P-value: 6.76E-06
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Prostate cancer
Example drug Gefitinib Phase 2 [468104], [536223], [1572592]
Tissue Prostate
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.59
Z-score: -0.82
P-value: 7.43E-04
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Psoriasis
Example drug PD-153035 Discontinued in Phase 1 [545893], [1572592]
Tissue Skin
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.27
Z-score: -0.42
P-value: 1.86E-07
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: 1.02
Z-score: 1.93
P-value: 1.31E-21
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Eosinophilic gastritis
Example drug Heparin-EGF-like factor Terminated [533768], [533866], [1572592]
Tissue Gastric antrum tissue
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: 0.21
Z-score: 1.30
P-value: 7.00E-02
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Disease Ureter cancer
Tissue Urothelium
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.07
Z-score: -0.71
P-value: 5.34E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Target Gene Expression Profiles in Other Tissues of Healthy Individuals
Reference
Ref
Ref 545893Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005268)
Ref 538585FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059.
Ref 550580Clinical pipeline report, company report or official report of Daiichi Sankyo.
Ref 550582Clinical pipeline report, company report or official report of Daiichi Sankyo.
Ref 468098(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4920).
Ref 468104(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4941).
Ref 541939(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6882).
Ref 542692(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7719).
Ref 5274662004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.